Stivarga (regorafenib) is specifically approved for use after other treatments have already been tried, which is why many people think of it as a last resort. That framing isn’t quite wrong, but it’s not the full picture either. Stivarga is a later-line therapy, meaning it’s used when earlier treatments stop working. But “last resort” implies nothing else follows, and that’s not always the case.
Where Stivarga Falls in the Treatment Sequence
The FDA approved Stivarga for three types of cancer, and in each case, it’s only used after patients have already gone through specific prior treatments:
- Metastatic colorectal cancer: Patients must have already received multiple rounds of standard chemotherapy, a drug that blocks blood vessel growth to tumors, and (for certain tumor types) a therapy targeting the EGFR protein. This typically makes Stivarga a third-line or later option.
- Gastrointestinal stromal tumors (GIST): Patients must have already been treated with imatinib and sunitinib, placing Stivarga in the third-line position.
- Liver cancer (hepatocellular carcinoma): Patients must have previously been treated with sorafenib, making Stivarga a second-line therapy.
So yes, Stivarga comes late in the treatment sequence. In colorectal cancer, it’s often one of the last standard options available. But it’s not necessarily the final drug a patient receives. Clinical guidelines list Stivarga alongside another oral medication called trifluridine/tipiracil as options at this stage, and doctors choose between them based on a patient’s individual situation. Some patients go on to receive the other drug afterward, or enter a clinical trial.
Treatment Order Can Matter
For colorectal cancer, research suggests the order in which later-line drugs are given may affect outcomes. One study found that patients who took Stivarga first and then switched to trifluridine/tipiracil had a median overall survival of 11.5 months, compared to 7.6 months for those who received the drugs in the opposite order. Another study (called REVERCE) found that for patients with a specific tumor type (KRAS wild-type), taking Stivarga before cetuximab-based therapy led to longer survival than the reverse sequence.
These findings are why oncologists pay close attention to sequencing rather than simply saving Stivarga for when all else fails. Using it at the right moment in the treatment plan, not just the last moment, can make a meaningful difference.
What the Survival Data Shows
The landmark trial that led to Stivarga’s approval in colorectal cancer (called the CORRECT trial) compared it to a placebo in patients whose cancer had progressed through all standard treatments. Median overall survival was 6.4 months with Stivarga versus 5.0 months with placebo. That 1.4-month difference is modest in absolute terms, and it’s important to go in with realistic expectations. This is a drug that can slow cancer progression in a difficult-to-treat setting, not one that typically produces dramatic tumor shrinkage.
For liver cancer, the RESORCE trial confirmed that Stivarga significantly improved both overall survival and the time before the cancer worsened compared to placebo, establishing it as a standard second-line option after sorafenib.
Side Effects and How Dosing Has Changed
Stivarga’s side effects are a major part of the conversation. About 60% of patients develop hand-foot skin reaction, a painful condition where the palms and soles become red, swollen, and blistered. Roughly 20% experience a severe form of this reaction. Other common issues include fatigue, high blood pressure, and abdominal pain.
The standard dose is 160 mg daily for three weeks out of every four-week cycle. But a clinical trial called ReDOS changed how many oncologists prescribe it. That study tested starting patients at half the standard dose (80 mg) and increasing by 40 mg each week only if side effects remained manageable. Patients on this gradual approach were significantly more likely to continue treatment into a third cycle: 43% versus 26% of those who started at the full dose. Side effects were also less frequent. Many oncologists now use this dose-escalation strategy as the default approach.
If your doctor suggests starting at a lower dose and working up, this is why. Staying on the drug longer at a tolerable dose often matters more than starting at the maximum dose and having to stop early.
Who Is Eligible for Stivarga
Stivarga is not appropriate for every patient whose earlier treatments have stopped working. Clinical trials and real-world use have generally required patients to have good enough physical function to handle daily activities with minimal limitation. In clinical studies, patients needed to be relatively functional, typically able to carry out all self-care and light activities. Patients who spend most of their day in bed or a chair are generally not considered candidates because the side effects are unlikely to be tolerable and the benefits less certain.
For liver cancer specifically, the approval was based on patients who had previously tolerated sorafenib. This is a meaningful detail: it means the drug was studied in patients whose livers were functioning well enough to handle a similar type of therapy.
Affording Stivarga
Stivarga is expensive, and cost is a real barrier for many patients. Bayer, the manufacturer, offers several programs to help. Commercially insured patients may qualify for a co-pay program that covers out-of-pocket costs, with up to $25,000 in annual savings. This program does not apply to patients on Medicare, Medicaid, or other government insurance.
For uninsured patients or those whose insurance doesn’t cover the drug, the Bayer U.S. Patient Assistance Foundation may provide Stivarga at no cost to patients who meet income requirements. Bayer also runs an Access Services program (1-800-288-8374) that helps with insurance verification, finding a specialty pharmacy, and navigating prior authorization or denial appeals.
How Stivarga Works Differently
Part of the reason Stivarga is used later in treatment is that it works broadly rather than targeting a single vulnerability. It blocks multiple proteins involved in tumor growth, blood vessel formation that feeds tumors, the spread of cancer to new sites, and signals from the tissue surrounding the tumor. This wide net means it can still have an effect even after cancers have found ways around more narrowly targeted earlier treatments. It’s this broad mechanism that makes it useful when more specific therapies have been exhausted, but it also explains why the side effects are wide-ranging.